Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

NCT04608630 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

450

Enrollment

OTHER

Sponsor class

Conditions

Critical Illness
Osteoporosis

Interventions

DRUG: Denosumab 60 MG/ML
DRUG: Zoledronic Acid 5Mg/Bag 100Ml Inj
DRUG: Sodium Chloride 0.9% or 5% Dextrose Intravenous
DRUG: Sodium Chloride 0.9% Injection

Sponsor

Australian and New Zealand Intensive Care Research Centre